Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on Endava, Raises Price Target to $165

Needham analyst Mayank Tandon maintains Endava (NYSE:DAVA) with a Buy and raises the price target from $120 to $165.

byBenzinga Newsdesk

August 27, 2021

1 minute read

Needham analyst Mayank Tandon maintains Endava (NYSE:DAVA) with a Buy and raises the price target from $120 to $165.

Roth Capital Initiates Coverage On Spartan Acquisition with Buy Rating, Announces Price Target of $15

By Benzinga Newsdesk

Today, 10:13 PM

Roth Capital analyst Philip Shen initiates coverage on Spartan Acquisition (NYSE:SPRQ) with a Buy rating and announces Price Target of $15.

SPRQ

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $130

By Benzinga Newsdesk

Today, 10:13 PM

Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $123 to $130.

ASND

Analyst Ratings

Expert Ratings For HubSpot

By Benzinga Insights

Today, 10:13 PM

Analysts have provided the following ratings for HubSpot (NYSE:HUBS) within the last quarter:

HUBS

$1000 Invested In Ross Stores 15 Years Ago Would Be Worth This Much Today

By Benzinga Insights

Today, 10:13 PM

Ross Stores (NASDAQ:ROST) has outperformed the market over the past 15 years by 5.34% on an annualized basis producing an average annual return of 11.81%. Currently, Ross Stores has a market capitalization of $28.31 billion.

ROST

Needham Maintains Buy on Endava, Raises Price Target to $165

Related Posts

Roth Capital Initiates Coverage On Spartan Acquisition with Buy Rating, Announces Price Target of $15

Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $130

Expert Ratings For HubSpot

$1000 Invested In Ross Stores 15 Years Ago Would Be Worth This Much Today